Leavell Investment Management Trimmed Its Texas Instrs (TXN) Holding; Lagoda Investment Management LP Boosted Its Regeneron Pharmaceuticals (REGN) Stake

June 19, 2018 - By Hilary Hom

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Leavell Investment Management Inc decreased Texas Instrs Inc (TXN) stake by 9.21% reported in 2018Q1 SEC filing. Leavell Investment Management Inc sold 3,886 shares as Texas Instrs Inc (TXN)’s stock rose 1.76%. The Leavell Investment Management Inc holds 38,289 shares with $3.98M value, down from 42,175 last quarter. Texas Instrs Inc now has $112.30B valuation. The stock decreased 1.29% or $1.5 during the last trading session, reaching $114.39. About 2.10M shares traded. Texas Instruments Incorporated (NASDAQ:TXN) has risen 38.09% since June 19, 2017 and is uptrending. It has outperformed by 25.52% the S&P500. Some Historical TXN News: ; 24/04/2018 – Texas Instruments Sees 2Q Rev $3.78B-$4.1B; 30/05/2018 – From vehicles to the factory, Tl mmWave sensors create a smarter world; 30/04/2018 – TEXAS INSTRUMENTS PRICES $1.3B OF INVESTMENT GRADE NOTES; 24/04/2018 – Texas Instruments 1Q EPS $1.35; 25/04/2018 – TEXAS INSTRUMENTS INC TXN.O : DEUTSCHE BANK RAISES TARGET PRICE TO $107 FROM $105; 24/04/2018 – Texas Instruments 2Q Guidance Higher Than Analyst Expectations (Video); 30/04/2018 – Texas Instruments prices $1.3 billion of investment grade notes; 24/04/2018 – Texas Instruments powers higher as sales, profit jump; 19/04/2018 – Texas Instruments Closes Below 50-Day Moving Average; 19/04/2018 – Boston Semi Equipment Recognized for Excellence by Texas Instruments

Lagoda Investment Management Lp increased Regeneron Pharmaceuticals (REGN) stake by 3.54% reported in 2018Q1 SEC filing. Lagoda Investment Management Lp acquired 2,282 shares as Regeneron Pharmaceuticals (REGN)’s stock declined 9.59%. The Lagoda Investment Management Lp holds 66,660 shares with $22.96M value, up from 64,378 last quarter. Regeneron Pharmaceuticals now has $34.01B valuation. The stock increased 0.10% or $0.31 during the last trading session, reaching $315.61. About 537,589 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 35.54% since June 19, 2017 and is downtrending. It has underperformed by 48.11% the S&P500. Some Historical REGN News: ; 10/03/2018 – Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need; 10/03/2018 – Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage; 03/05/2018 – REGENERON PHARMACEUTICALS INC – QTRLY PRALUENT GLOBAL SALES $60 MLN VS $36 MLN; 21/03/2018 – Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis; 10/03/2018 – Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need; 21/03/2018 – Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection; 01/05/2018 – Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable P; 03/05/2018 – Regeneron Pharma 1Q Net $478M; 03/04/2018 – STAT Plus: Sanofi and Regeneron encounter more payer resistance over new eczema drug – this time, in the U.K; 01/05/2018 – REGENERON & SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB)

Investors sentiment decreased to 1.05 in 2018 Q1. Its down 0.12, from 1.17 in 2017Q4. It fall, as 70 investors sold REGN shares while 158 reduced holdings. 71 funds opened positions while 169 raised stakes. 69.33 million shares or 0.23% more from 69.17 million shares in 2017Q4 were reported. Wetherby Asset Mngmt Inc, a California-based fund reported 1,013 shares. Fjarde Ap stated it has 0.12% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). New York-based Millennium Mgmt Llc has invested 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Icon Advisers owns 0.08% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 3,000 shares. Fukoku Mutual Life Insurance accumulated 390 shares. 1,944 are owned by Caxton Assoc L P. Baystate Wealth Management Ltd Limited Liability Company stated it has 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Parametric Port Assocs Lc reported 0.06% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Plante Moran Fin Advsrs Ltd Limited Liability Company accumulated 95 shares. Hall Laurie J Trustee invested 0.03% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Timber Hill Ltd Llc invested 0.1% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Bb&T Securities Ltd Liability has invested 0.03% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Toronto Dominion Retail Bank has 41,759 shares for 0.03% of their portfolio. Tiaa Cref Invest Mgmt Llc invested in 210,633 shares or 0.05% of the stock. Gabelli Funds Limited Liability Corporation has invested 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Lagoda Investment Management Lp decreased Tesla Inc (NASDAQ:TSLA) stake by 2,190 shares to 36,688 valued at $9.76M in 2018Q1. It also reduced Ubiquiti Networks Inc (NASDAQ:UBNT) stake by 28,528 shares and now owns 73,345 shares. Monsanto Co New (NYSE:MON) was reduced too.

Since February 9, 2018, it had 0 insider purchases, and 6 selling transactions for $48.41 million activity. GOLDSTEIN JOSEPH L also sold $680,000 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Wednesday, March 14. 121,601 shares were sold by Sanofi, worth $37.61 million on Friday, June 8. SING GEORGE L sold $5.72 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Wednesday, May 9. Another trade for 11,407 shares valued at $3.37 million was made by STAHL NEIL on Wednesday, May 23.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 11 have Buy rating, 1 Sell and 21 Hold. Therefore 33% are positive. Regeneron Pharmaceuticals Inc. had 127 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Monday, October 16 with “Hold”. UBS maintained the shares of REGN in report on Thursday, September 21 with “Buy” rating. Chardan Capital Markets downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Monday, January 25. Chardan Capital Markets has “Sell” rating and $400 target. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Market Perform” rating given on Monday, June 26 by Bernstein. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Friday, October 2. The firm has “Hold” rating given on Wednesday, December 13 by RBC Capital Markets. The firm earned “Neutral” rating on Monday, August 10 by TH Capital. The firm has “Hold” rating by Oppenheimer given on Wednesday, June 14. The firm earned “Buy” rating on Friday, July 21 by Piper Jaffray. RBC Capital Markets maintained the shares of REGN in report on Wednesday, August 5 with “Outperform” rating.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Seekingalpha.com which released: “Zoetis teams up with Regeneron to discover new vet treatments” on June 06, 2018, also Seekingalpha.com with their article: “Kiniksa Pharmaceuticals IPO: Cash King” published on May 24, 2018, Fool.com published: “Should CRISPR Stock Investors Worry About Cancer?” on June 13, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Streetinsider.com and their article: “Sanofi (SNY), Regeneron (REGN) Announce NEJM Published Pivotal Cemiplimab Trials showing Positive Results in …” published on June 04, 2018 as well as Prnewswire.com‘s news article titled: “Regeneron’s Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak” with publication date: May 31, 2018.

More news for Texas Instruments Incorporated (NASDAQ:TXN) were recently published by: Prnewswire.com, which released: “TI’s new high-voltage amplifiers enable accuracy in error-sensitive industrial applications” on June 19, 2018. Fool.com‘s article titled: “Here’s Why Texas Instruments Inc. Shares Rose 10.3% In May” and published on June 07, 2018 is yet another important article.

Investors sentiment decreased to 0.9 in 2018 Q1. Its down 0.11, from 1.01 in 2017Q4. It dropped, as 65 investors sold TXN shares while 408 reduced holdings. 119 funds opened positions while 308 raised stakes. 800.61 million shares or 0.62% less from 805.57 million shares in 2017Q4 were reported. Mississippi-based Hancock Hldg has invested 0.07% in Texas Instruments Incorporated (NASDAQ:TXN). Aristotle Cap Mgmt Ltd Liability Corp, California-based fund reported 18,126 shares. Burney holds 0.19% or 28,810 shares in its portfolio. Hightower Ltd Liability Com reported 237,538 shares or 0.21% of all its holdings. Jfs Wealth Ltd reported 48 shares or 0% of all its holdings. Natl Pension Ser holds 0.43% of its portfolio in Texas Instruments Incorporated (NASDAQ:TXN) for 840,728 shares. Douglass Winthrop Advisors Ltd holds 0.04% of its portfolio in Texas Instruments Incorporated (NASDAQ:TXN) for 7,600 shares. Wallington Asset Mgmt Ltd Limited Liability Company reported 3.33% of its portfolio in Texas Instruments Incorporated (NASDAQ:TXN). Moreover, Spectrum Asset Inc (Nb Ca) has 0.19% invested in Texas Instruments Incorporated (NASDAQ:TXN) for 2,100 shares. Apg Asset Nv reported 3.19 million shares stake. Timber Hill Limited Liability Com has 0.16% invested in Texas Instruments Incorporated (NASDAQ:TXN) for 10,193 shares. Georgia-based Decatur Management has invested 2.32% in Texas Instruments Incorporated (NASDAQ:TXN). Pinnacle Fincl Prns holds 0.09% in Texas Instruments Incorporated (NASDAQ:TXN) or 8,950 shares. Weitz Inv Mgmt holds 1.73% of its portfolio in Texas Instruments Incorporated (NASDAQ:TXN) for 394,270 shares. 5,679 were accumulated by Lombard Odier Asset (Switzerland).

Among 42 analysts covering Texas Instruments (NASDAQ:TXN), 19 have Buy rating, 3 Sell and 20 Hold. Therefore 45% are positive. Texas Instruments had 119 analyst reports since July 24, 2015 according to SRatingsIntel. Barclays Capital maintained Texas Instruments Incorporated (NASDAQ:TXN) rating on Tuesday, July 18. Barclays Capital has “Equal-Weight” rating and $83 target. The rating was initiated by Susquehanna on Wednesday, December 21 with “Positive”. Bernstein maintained the stock with “Buy” rating in Wednesday, January 24 report. The stock has “Outperform” rating by Bernstein on Tuesday, September 13. The company was maintained on Monday, July 3 by Stifel Nicolaus. The firm earned “Buy” rating on Friday, September 29 by RBC Capital Markets. On Thursday, October 27 the stock rating was maintained by Cowen & Co with “Market Perform”. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, August 31. The stock has “Buy” rating by Ascendiant Capital Markets on Thursday, July 23. The rating was maintained by Mizuho with “Neutral” on Wednesday, January 25.

Leavell Investment Management Inc increased Bb&T Corp (NYSE:BBT) stake by 18,950 shares to 25,053 valued at $1.30M in 2018Q1. It also upped Vanguard Index Fds (VV) stake by 16,150 shares and now owns 152,059 shares. Total Sys Svcs Inc (NYSE:TSS) was raised too.

Texas Instruments Incorporated (NASDAQ:TXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: